Today, Zacks Investment Ideas feature highlights Gilead Sciences GILD and Johnson & Johnson JNJ. Buy Gilead Sciences (GILD ...
Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back ...
Gilead Sciences's GILD short percent of float has risen 6.47% since its last report. The company recently reported that it ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
News-Medical.Net on MSN1d
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIVGilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback